Overall rank by patents
#25,126
Across all tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 11 technology areas, active 2015–2017. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: H04B (TRANSMISSION).
The verdict
Sequans holds 11 US patents across 11 technology areas, rank #25,126 of 50,000 tracked assignees.
Sequans Communications Ltd. has been granted 11 US utility patents between 2015 and 2017, placing Sequans Communications Ltd. at rank #25,126 across all assignees tracked by PlainPatent. This portfolio spans 11 distinct Cooperative Patent Classification (CPC) subclasses, averaging 10.4 claims per patent with primary concentration in H04B (TRANSMISSION). As a Foreign Corporation, Sequans Communications Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, Sequans sits between Sekisui Specialty Chemicals America, Llc (11 patents, rank #25,122) and Shanghai Hansoh Biomedical Co., Ltd (11 patents, rank #25,130) - the closest US assignees by grant volume. The composite Innovation Score of 26.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 0 grants, compared with 11 in the 2015–2019 window, a -100% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Sequans Communications Ltd.'s 10.4 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 11 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Sequans Communications Ltd. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
SEKISUI SPECIALTY CHEMICALS AMERICA, LLC
11 patents
SELF-SUSPENDING PROPPANT LLC
11 patents
SEMCO LLC
11 patents
SEN CORPORATION
11 patents
SFS Group International AG
11 patents
SHANDONG COMPUTER SCIENCE CENTER (NATIONAL SUPERCOMPUTER CENTER IN JINAN)
11 patents
SHANDONG NORMAL UNIVERSITY
11 patents
SHANGHAI HANSOH BIOMEDICAL CO., LTD
11 patents
SEQUANS COMMUNICATIONS LTD.
11 patents
What this shows Sequans holds 11 patents at rank #25,126, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Sequans's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
27 Top 79% higher than 21% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 6 | 54.5% |
| 2016 | 4 | 36.4% |
| 2017 | 1 | 9.1% |
Top 11 of 11 technology areas
Overall rank by patents
#25,126
Across all tracked assignees
26.6 out of 100
How to use this portfolio
Sequans's 11 grants land it in the top 79% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.